CA2369616C - Somatic transgene immunization and related methods - Google Patents

Somatic transgene immunization and related methods Download PDF

Info

Publication number
CA2369616C
CA2369616C CA002369616A CA2369616A CA2369616C CA 2369616 C CA2369616 C CA 2369616C CA 002369616 A CA002369616 A CA 002369616A CA 2369616 A CA2369616 A CA 2369616A CA 2369616 C CA2369616 C CA 2369616C
Authority
CA
Canada
Prior art keywords
cell
nucleic acid
epitopes
epitope
response
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CA002369616A
Other languages
English (en)
French (fr)
Other versions
CA2369616A1 (en
Inventor
Maurizio Zanetti
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Nevagen LLC
Original Assignee
Nevagen LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=23161331&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CA2369616(C) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from US09/300,959 external-priority patent/US7279462B1/en
Application filed by Nevagen LLC filed Critical Nevagen LLC
Publication of CA2369616A1 publication Critical patent/CA2369616A1/en
Application granted granted Critical
Publication of CA2369616C publication Critical patent/CA2369616C/en
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70514—CD4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70517—CD8
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/20—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans from protozoa
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/74—Inducing cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Cell Biology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Oncology (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Biological Depolymerization Polymers (AREA)
CA002369616A 1999-04-27 2000-04-27 Somatic transgene immunization and related methods Expired - Fee Related CA2369616C (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US09/300,959 US7279462B1 (en) 1998-04-27 1999-04-27 Somatic transgene immunization and related methods
US09/300,959 1999-04-27
PCT/US2000/011372 WO2000064488A2 (en) 1999-04-27 2000-04-27 Somatic transgene immunization and related methods

Publications (2)

Publication Number Publication Date
CA2369616A1 CA2369616A1 (en) 2000-11-02
CA2369616C true CA2369616C (en) 2009-09-15

Family

ID=23161331

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002369616A Expired - Fee Related CA2369616C (en) 1999-04-27 2000-04-27 Somatic transgene immunization and related methods

Country Status (7)

Country Link
US (1) US20080076175A1 (enExample)
EP (1) EP1181320B1 (enExample)
JP (2) JP5000807B2 (enExample)
AT (1) ATE501175T1 (enExample)
CA (1) CA2369616C (enExample)
DE (1) DE60045707D1 (enExample)
WO (1) WO2000064488A2 (enExample)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7279462B1 (en) 1998-04-27 2007-10-09 Nevagen Llc Somatic transgene immunization and related methods
GB0102145D0 (en) 2001-01-26 2001-03-14 Scancell Ltd Substances
EP1887084A1 (en) * 2006-08-10 2008-02-13 International Investment and Patents SA Plasmids with immunological action
GB0706070D0 (en) 2007-03-28 2007-05-09 Scancell Ltd Nucleic acids
JOP20190271A1 (ar) * 2017-05-24 2019-11-21 Novartis Ag بروتينات مطعّمة بسيتوكين- الجسم المضاد وطرق الاستخدام للاضطرابات المتعلقة بالمناعة

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69023900D1 (de) * 1989-02-24 1996-01-11 Univ California Gentechnologisch veränderte immunglobuline.
US5703055A (en) * 1989-03-21 1997-12-30 Wisconsin Alumni Research Foundation Generation of antibodies through lipid mediated DNA delivery
US5969109A (en) * 1990-02-28 1999-10-19 Bona; Constantin Chimeric antibodies comprising antigen binding sites and B and T cell epitopes
US6977074B2 (en) * 1997-07-10 2005-12-20 Mannkind Corporation Method of inducing a CTL response
US5891432A (en) * 1997-07-29 1999-04-06 The Immune Response Corporation Membrane-bound cytokine compositions comprising GM=CSF and methods of modulating an immune response using same
US7279462B1 (en) * 1998-04-27 2007-10-09 Nevagen Llc Somatic transgene immunization and related methods
US6306640B1 (en) * 1998-10-05 2001-10-23 Genzyme Corporation Melanoma antigenic peptides

Also Published As

Publication number Publication date
JP5000807B2 (ja) 2012-08-15
WO2000064488A2 (en) 2000-11-02
JP2002542305A (ja) 2002-12-10
DE60045707D1 (de) 2011-04-21
EP1181320B1 (en) 2011-03-09
WO2000064488A3 (en) 2001-05-10
ATE501175T1 (de) 2011-03-15
US20080076175A1 (en) 2008-03-27
WO2000064488A9 (en) 2002-07-11
JP2009102369A (ja) 2009-05-14
CA2369616A1 (en) 2000-11-02
EP1181320A2 (en) 2002-02-27

Similar Documents

Publication Publication Date Title
Donnelly et al. Immunization with DNA
US7118751B1 (en) DNA vaccines encoding antigen linked to a domain that binds CD40
Cohen et al. Modulating the immune response to genetic immunization
JP4764585B2 (ja) タンパク質抗原およびペプチド抗原の免疫原性を増強するためのｆｃ融合タンパク質
US20130183347A1 (en) Somatic Transgene Immunization and Related Methods
TW201938793A (zh) 一種新型疫苗佐劑
US7279555B2 (en) Advanced antigen presentation platform
US20080076175A1 (en) Somatic transgene immunization and related methods
JP4836957B2 (ja) ワクチンとしての、組換えマイコバクテリウムおよび生物学的に活性な作用剤の組合せ
US8372409B2 (en) Dendritic cell binding proteins and uses thereof
JP2022536850A (ja) Ｂ型肝炎ウイルス（ｈｂｖ）ワクチンおよび抗ｐｄ－１または抗ｐｄ－ｌ１抗体の組合せ
US20090074814A1 (en) DNA Vaccines Encoding Antigen Linked to a Domain That Binds CD40
JP2022537324A (ja) Ｂ型肝炎ウイルス（ｈｂｖ）ワクチンおよび抗ｐｄ－１抗体の組合せ
US7354759B2 (en) DNA vaccines expressing hypervariable VH-CDR3 idiotypic determinants
Godillot et al. DNA vaccination as an anti-inflammatory strategy
Davis Gene-based vaccines
AU2008238215A1 (en) Ig-pConsensus gene vaccination protects from antibody-dependent immune pathology in autoimmune disease
EP0805207A1 (en) Polycistronic expression plasmid for tumor rejection
HK1106929B (zh) 作为疫苗的重组分枝杆菌和生物活性剂的组合

Legal Events

Date Code Title Description
EEER Examination request
MKLA Lapsed

Effective date: 20160427